Fahim Ibrahim's research while affiliated with Government of Ontario, Canada and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (2)
The aim of this study was to assess the effectiveness of dorzolamide-timolol (DT) in the management of open-angle glaucoma (OAG) and ocular hypertension.
An open-label, 12-week, multicenter, Canadian study was conducted. Patients with untreated OAG or ocular hypertension received DT for 12 weeks to reduce intraocular pressure (IOP). If target IOP w...
To assess the effect of preservative-free dorzolamide-timolol on nonvisual symptoms and intraocular pressure (IOP) in newly diagnosed and untreated patients with open-angle glaucoma or ocular hypertension.
This was a prospective, 8-week, open-label, Canadian multicenter study. All patients were treated with preservative-free dorzolamide-timolol for...
Citations
... Evidence gleaned from both clinical trials and real-world studies long has suggested that this fixed-dose combination offers important clinical benefits which compare favorably to other treatment options in terms of sustained IOP reduction, long-term IOP control, and patient tolerability. [71][72][73][74][75][76][77][78][79][80][81][82][83][84][85][86][87] Future availability of preservative-free formulations in developing world may offer important advantages that weigh favorably in the cost/benefit and cost/effectiveness calculus. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/817571381133316-1571935615183_Q64/Andrew-Crichton.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1017972076343296-1619714864172_Q64/Paul-Harasymowycz.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272540123791380-1441990037363_Q64/Cindy-Hutnik.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272471127490570-1441973587471_Q64/John-Sampalis.jpg)
... Often, patients with glaucoma require lifetime topical therapy and OSD has been reported in up to 59% of patients [4,5]. Preservatives in topical antiglaucoma drops disrupt the ocular surface by a variety of mechanisms resulting in decreased tear film stability and increased evaporation [6,7]. The side effects of preserved eye drop administration include ocular hyperemia, burning, stinging, and itching that are exacerbated by an unstable tear film [7]. ...
